John Murphy, M.D., M.P.H., D.P.H. Covid-19LOng-haul Foundation<\/p>\n\n\n\n
Post\u2011acute sequelae of SARS\u2011CoV\u20112 infection (PASC), commonly known as long\u2011COVID, is a multisystem disorder affecting 10\u201320% of patients following acute infection. Among its varied manifestations, peripheral nerve neuropathy\u2014particularly small\u2011fiber neuropathy (SFN)<\/strong>\u2014has emerged as a frequent, disabling sequela characterized by pain, paresthesia, and dysautonomia. Evidence suggests that peripheral neuropathy following COVID\u201119 results not from direct viral persistence but from post\u2011infectious immune dysregulation, autonomic dysfunction, and inflammatory processes. Objective neurophysiologic and histologic studies demonstrate SFN in long\u2011COVID cohorts, implicating immune mechanisms and sometimes autoantibodies. This paper reviews current knowledge on etiology, genomic susceptibility, immunopathology, physiological mechanisms, diagnostic strategies, and clinical treatment paradigms for long\u2011COVID\u2013associated neuropathy, with an emphasis on multidisciplinary insights and immunologic underpinnings.<\/p>\n\n\n\n The clinical syndrome of long\u2011COVID encompasses a broad range of persistent symptoms lasting beyond 12\u202fweeks after acute SARS\u2011CoV\u20112 infection. These include fatigue, cognitive impairment (\u201cbrain fog\u201d), pain, and autonomic dysfunction. Peripheral neuropathic symptoms\u2014particularly burning pain, numbness, and autonomic disturbances\u2014are increasingly recognized and frequently linked to small\u2011fiber neuropathy (SFN). A 2024 case\u2011control study found that approximately 50% of patients with painful long\u2011COVID met diagnostic criteria for SFN on quantitative sensory testing or skin biopsy.<\/p>\n\n\n\n Peripheral nerve involvement in PASC is not restricted to large\u2011fiber neuropathy; indeed, small unmyelinated (C) and thinly myelinated (A\u03b4) fibers mediating pain and autonomic function are often implicated, resulting in both sensory and autonomic symptoms ranging from burning pain to orthostatic intolerance.<\/p>\n\n\n\n Evidence strongly suggests that peripheral neuropathy in long COVID is predominantly immune\u2011mediated rather than due to persistent viral replication. Data from peripheral neuropathy evaluations show that patients with PASC often lack antecedent risk factors for neuropathy yet develop symptoms within weeks of acute SARS\u2011CoV\u20112 infection.<\/p>\n\n\n\n Post\u2011infectious immune dysregulation may involve aberrant activation of both innate and adaptive immune pathways. Several studies describe inflammatory markers in a substantial proportion of PASC patients. Moreover, autoantibodies isolated from long\u2011COVID patients\u2014when passively transferred to mice\u2014induce neurological deficits, including small fiber damage, indicating the potential for autoimmune mechanisms in neuropathy pathogenesis.<\/p>\n\n\n\n SARS\u2011CoV\u20112\u2013induced endothelial dysfunction and microvascular injury could contribute to ischemic damage of peripheral nerve fibers. Although direct viral invasion of nerves is less convincingly demonstrated, vascular dysregulation and low\u2011grade inflammation affecting the vasa nervorum may compromise nerve perfusion, exacerbating neuropathic symptoms.<\/p>\n\n\n\n Small nerve fibers play key roles in autonomic regulation (heart rate, sweating, GI motility). In PASC, dysautonomia (e.g., postural orthostatic tachycardia syndrome [POTS]\u2013like symptoms) is frequently observed, often overlapping with SFN. A study found cerebrovascular and autonomic dysregulation in PASC patients similar to POTS patients, highlighting overlapping pathophysiology involving small fiber and autonomic dysfunction.<\/p>\n\n\n\n Genetic predisposition may influence the risk of developing long\u2011COVID neuropathy. Variants in HLA loci and genes involved in immune regulation could predispose individuals to persistent post\u2011infectious immune activation and autoimmunity. Although detailed genomic studies specifically addressing PASC\u2011associated neuropathy are still emergent, broader genomic analyses implicate host factors in long COVID susceptibility, including pathways related to immune signaling and inflammation.<\/p>\n\n\n\n Emerging work on long COVID proteomic and network analyses identifies mitochondrial dysfunction, thromboinflammatory pathways, and neural inflammation as important factors, suggesting that genetic and molecular regulation of immune and inflammatory networks may contribute to neuropathy.<\/p>\n\n\n\n In PASC, persistent low\u2011grade inflammation can involve elevated cytokines and immune cell activation. While heterogeneity exists, elevated inflammatory markers have been observed in many PASC cohorts, implying ongoing immune system perturbations.<\/p>\n\n\n\n Autoantibody production post\u2011SARS\u2011CoV\u20112 infection may contribute to neuropathic processes. The transfer of IgG from long\u2011COVID patients to animal models produced neurological symptoms and small fiber nerve damage, suggesting pathogenic autoantibodies targeting peripheral nerve elements.<\/p>\n\n\n\n SARS\u2011CoV\u20112 shares peptide sequences with host proteins, positing a mechanism of molecular mimicry that could trigger autoimmune responses against peripheral nerve components, although direct evidence linking specific mimics to SFN in long COVID is still under investigation.<\/p>\n\n\n\n SFN involves damage to thinly myelinated A\u03b4 and unmyelinated C fibers, disrupting nociception and autonomic regulation. Skin biopsy studies from long\u2011COVID patients show reduced intraepidermal nerve fiber density in a large proportion of cases while nerve conduction studies often remain normal, reflecting selective small fiber involvement.<\/p>\n\n\n\n Quantitative sensory testing (QST) and laser evoked potentials can reveal sensory dysfunction corresponding to SFN. These objective measures complement histological findings, and in some cohorts QST shows high sensitivity for detecting small fiber damage.<\/p>\n\n\n\n SFN often co\u2011exists with autonomic abnormalities such as orthostatic intolerance, heart rate variability changes, and sudomotor dysfunction. Such symptoms reflect disruption of small fibers innervating autonomic targets and may manifest independent of detectable sensory neuropathy on standard tests.<\/p>\n\n\n\n Patients with long\u2011COVID\u2013associated neuropathy commonly report burning pain, paresthesias, numbness, and dysesthesia<\/strong> affecting distal extremities, often accompanied by autonomic symptoms<\/strong> (palpitations, GI dysmotility, orthostatic intolerance). Symptoms may vary in distribution and severity and often persist for months. Full thickness skin biopsy remains the diagnostic gold standard for SFN, with quantitative sensory testing and autonomic function testing supportive.<\/p>\n\n\n\n Neuropathic pain is commonly treated with FDA\u2011approved agents such as gabapentinoids, SNRIs (duloxetine), and TCAs (nortriptyline), tailored to symptom severity and patient tolerability.<\/p>\n\n\n\n Emerging case series suggest that immunotherapies\u2014corticosteroids, intravenous immunoglobulin (IVIG), and plasmapheresis\u2014may benefit subsets of patients with suspected immune\u2011mediated SFN. In one cohort of PASC neuropathy patients, 65% received immunotherapies with partial improvements documented. Controlled clinical trials are lacking, but immunomodulation is often considered when symptoms are severe and immune markers are present.<\/p>\n\n\n\n Physical therapy, pain rehabilitation programs, and autonomic retraining can improve functional status. Psychological support is critical given the chronic nature of symptoms.<\/p>\n\n\n\n Targeted therapies addressing specific immune pathways (e.g., B\u2011cell depletion, cytokine blockade) remain under investigation. Genetic and biomarker profiling may in future allow more personalized approaches.<\/p>\n\n\n\n Long\u2011COVID neuropathy exhibits variable trajectories. Some patients improve over 6\u201312 months with supportive care and targeted therapy, while others experience persistent symptoms. Longitudinal studies indicate that symptoms can gradually ameliorate, but many individuals continue to suffer chronic pain and dysautonomia beyond a year.<\/p>\n\n\n\n Research priorities include:<\/p>\n\n\n\n Peripheral neuropathy\u2014especially small\u2011fiber involvement\u2014is a significant component of PASC, driven predominantly by post\u2011infectious immune mechanisms and dysautonomia rather than persistent viral infection. Multidisciplinary evaluation including immunology, neurophysiology, and pathology is key to diagnosis and management. Although evidence for targeted treatments such as immunomodulation is emerging, further controlled studies are imperative to optimize outcomes.<\/p>\n\n\n\n John Murphy, M.D., M.P.H., D.P.H. Covid-19LOng-haul Foundation Abstract Post\u2011acute sequelae of SARS\u2011CoV\u20112 infection (PASC), commonly known as long\u2011COVID, is a multisystem disorder affecting 10\u201320% of patients following acute infection. Among […]<\/p>\n","protected":false},"author":2,"featured_media":14344,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[368,421],"tags":[],"class_list":["post-14341","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-neuropathy","category-pasc"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14341"}],"version-history":[{"count":3,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14341\/revisions"}],"predecessor-version":[{"id":14346,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14341\/revisions\/14346"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/14344"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n\n\n\nIntroduction<\/strong><\/h2>\n\n\n\n
\n\n\n\nEtiology<\/strong><\/h2>\n\n\n\n
Post\u2011Infectious Immune Dysregulation<\/strong><\/h3>\n\n\n\n
Microvascular and Endothelial Injury<\/strong><\/h3>\n\n\n\n
Autonomic Dysregulation<\/strong><\/h3>\n\n\n\n
\n\n\n\nGenomics and Host Susceptibility<\/strong><\/h2>\n\n\n\n
\n\n\n\nImmunopathology<\/strong><\/h2>\n\n\n\n
Immune Cell Activation and Cytokine Signatures<\/strong><\/h3>\n\n\n\n
Autoantibodies<\/strong><\/h3>\n\n\n\n
Molecular Mimicry<\/strong><\/h3>\n\n\n\n
\n\n\n\nPathology and Physiological Mechanisms<\/strong><\/h2>\n\n\n\n
Small Fiber Pathology<\/strong><\/h3>\n\n\n\n
Neurophysiological Alterations<\/strong><\/h3>\n\n\n\n
Autonomic Nervous System Dysfunction<\/strong><\/h3>\n\n\n\n
\n\n\n\nClinical Presentation<\/strong><\/h2>\n\n\n\n
\n\n\n\nDiagnostics<\/strong><\/h2>\n\n\n\n
\n
\n\n\n\nClinical Treatment<\/strong><\/h2>\n\n\n\n
Symptomatic Management<\/strong><\/h3>\n\n\n\n
Immunomodulatory Therapies<\/strong><\/h3>\n\n\n\n
Rehabilitation and Supportive Care<\/strong><\/h3>\n\n\n\n
Emerging and Experimental Strategies<\/strong><\/h3>\n\n\n\n
\n\n\n\nPrognosis and Outcomes<\/strong><\/h2>\n\n\n\n
\n\n\n\nFuture Directions<\/strong><\/h2>\n\n\n\n
\n
\n\n\n\nConclusion<\/strong><\/h2>\n\n\n\n
\n\n\n\nReferences<\/strong><\/h2>\n\n\n\n
\n